Lung Cancer

Lung Cancer

A profound understanding of the facetted characteristics and behavior of a tumor demands deep and integrated knowledge among clinical experts collaborating in interdisciplinary teams – a joint effort to empower personalized cancer care. By strategically combining advanced imaging, IT, and laboratory applications, lung cancer management can be improved through:

  • Early detection through screening programs to reduce lung cancer related mortality
  • Advanced lung cancer imaging to better visualize and characterize a tumor
  • Innovative treatment planning and management for improved outcomes and reduction of side effects
  • Individualized patient treatment and systematic assessment of therapy response to ensure treatment success

Whatever the clinical question, our innovative portfolio contains everything you need to offer patient care at the highest-possible level – from angiography, X-ray systems, MRI, CT, PET/CT, MR/PET, SPECT/CT, and clinical chemistry testing, through to interventional imaging, radiation oncology support, and systems designed for process optimization and efficient lung cancer workflows.

Explore on the following tabs how our advanced technologies and solutions help you look closer and see further – along the entire continuum of care.

Early detection & diagnosis

Treating late-stage lung cancer is extremely challenging. However, lung cancer treatment can be significantly more effective if the disease is detected earlier in stage I or II, before the onset of symptoms when the disease is still localized. This emphasizes the benefit to establish screening programs for earlier detection. Precise lung cancer staging of lymph node involvement and distant metastases determines the prognosis and is the foundation of adequate therapy selection.

Find out more about the benefits of lung cancer screening and its life-saving potential

AI rad companion body regions

The AI-Rad Companion, our family of AI-powered, cloud-based augmented workflows, helps you to reduce the burden of basic repetitive tasks and may increase your diagnostic precision when interpreting medical images.

Lung cancer screening -  Image reading and reporting with syngo.via
  • 3D reading and advanced visualization
  • designed for both routine and challenging cases
  • dedicated modality-specific applications
  • structured reporting (Lung-RADS™)
  • server-client concept

Lung cancer screening - Computed Tomography
Interventional CT procedure to biopsy a lung cancer lesion

What is the impact of CT screening on the lung-cancer mortality rate?
The authors of NELSON Study point out that "Lung-cancer mortality was significantly lower among those who underwent volume CT screening"2

  • Latest recommendation of the American Association of Physicists in Medicine3 qualifies the Siemens Healthineers CT scanners4 for low-dose Lung Cancer Screening (LCS).
  • Unique radiation dose-saving technologies also available for LCS protocols.
  • Tin filter technology optimizes X-ray spectral shaping for improved dose efficiency and early detection.
  • Lung CAD, a second reader tool, provides highly sensitive and specific detection of lung nodules. It is available with syngo.via as inline tool and with CT View&GO5.
  • Adaptive 3D Intervention Suite is designed to perform CT-guided interventions for further evaluation of suspicious findings and to fulfill country specific guidelines for lung nodules with a diameter ≥ 8 mm or a volume ≥ 300 mm6

Learn more about our CT portfolio

X-ray products  - Lung cancer screening
Effect of advanced image post-processing on Siemens Healthineers radiography images
  • all relevant Siemens Healthineers' X-ray systems can be configured with dedicated hard- and software for lung imaging
  • ClearRead Bone Suppression™ to suppress bone structures for a clearer, unobstructed view of soft tissue
  • ClearRead +Detect™ is an advanced computer-aided detection (CAD) technology that identifies areas on a chest X-ray that may be early-stage lung cancer

Positron Emission Tomography – Computed Tomography (PET/CT)  - Lung cancer screening
  • finest volumetric resolution7
  • fast, amplitude-based gating technology (HD•Chest) virtually freezes respiratory motion and helps improve lesion detectability in the thoracic and abdominal areas
  • FlowMotion™ continuous bed motion for routine imaging of motion-sensitive organs with the highest possible resolution

Magnetic Resonance Imaging (MRI) and Molecular MR (MR/PET)  - Lung cancer screening
Biograph mMR dataset of a lung cancer patient visualized in syngo.mMR General reader
  • robust MR techniques for lung imaging
  • unmatched soft-tissue contrast for infiltration assessment, surgery planning, and whole-body staging
  • multi-parametric MRI can provide information on cellular density, perfusion, and vascularity
  • DotGO workflow engines8, for standardized protocols and more predictable scan slots
  • Biograph mMR™ combines MRI’s anatomical and functional information with the high sensitivity of PET in one single simultaneous, integrated MRI and PET system

Targeting lung cancer – Shaping the future of lung cancer therapy

Lung cancer is a leading cause of death with over 2 Million new cases per year and over 1.7 Million deaths per year9. Because it is asymptomatic it is detected often too late with a poor survival prognosis: The 5-year survival rate is about 57% for patients with stage 1 disease and only ~4% for those with stage 410. With the implementation of lung cancer screening protocols for patients at risk, lung cancer can be detected in an early stage which could drastically improve survival chances11. Therefore, minimally-invasive treatment options with curative intent will come more and more into focus. Key-hole surgery, robotic interventions, local thermal ablation, hybrid approaches, navigation technology and targeted radiation therapy are currently investigated by leading hospitals. Consequently, patients will ask for these options.

Early stage lung cancer imposes challenges on therapy because of small targets and the natural deviation between accurate diagnostic findings and the situation during surgery, intervention or radiotherapy12. Siemens Healthineers provide image-guided solutions for non- and minimally- invasive lung cancer therapy to face these challenges. Many factors are impacting clinical outcomes. However, our vision is to contribute with our technology to lower survival rates, less complications and a better quality of life of cancer patients.

In particular, our robotic C-arm ARTIS pheno supports one-stop image-guided localization and resection of small pulmonary nodules in the Hybrid OR 13. Endobronchial interventions are supported cost efficiently with our mobile 3D C-arm Cios Spin. 14 Planning of stereotactic body-radiation therapy is supported through dedicated multi-modality imaging through our dedicated CT system SOMATOM go.Open Pro. For lung metastasis and medically inoperable patients image-guided percutaneous thermal ablation can potentially reduce the tumor burden 15. Artis Q ceiling has the tools for such procedures.

Monitoring & follow-up

Therapy monitoring and follow-up of lung cancer are key to individualized patient treatment. Monitoring the tumor’s response allows a timely adaptation to the selected therapy. This is important when several therapeutic options are available, as is the case with lung cancer.

After completion of the therapy, a systematic follow-up for the early detection of lung cancer relapse should always be part of the patient’s workup and is described in the corresponding guidelines.

Computed Tomography & syngo.via - Lung cancer therapy monitoring
CT follow-up examination consisting of baseline and two follow-up scans: evaluation and reporting are supported by syngo.via-based oncology applications
  • through functional examinations like tissue perfusion or iodine quantification SOMATOM CT systems enable an earlier assessment of tumor’s response in the lung or disease progression
  • syngo.via-based reading applications permit a standardized and efficient image analysis
  • longitudinal studies of the same patient are automatically registered, the trending of lesion size change is automatically visualized
  • structured reporting allows efficient communication across departments and disciplines

Positron Emission Tomography - Lung cancer therapy monitoring
SUV trending in a multi-timepoint PET/CT examination for response monitoring: the effects of the therapy are graphically visualized automatically
  • early predictor of response
  • advanced system calibration of Biograph PET/CT systems helps ensure consistent quantitative accuracy across multiple time points
  • Small, 4 mm LSO crystals provide high sensitivity in detecting local and distant recurrences of lung carcinoma
  • syngo.via with EQ•PET helps reduce technology-induced variations and inter-reader variability by normalizing PET SUV values between different scanners and reconstruction methods
  • Continuous bed motion, made possible by FlowMotion™ technology supports precise disease characterization in therapy monitoring of lung cancer


  • comprehensive menu of oncology tests, e.g. general and specific tests to assess side-effects in the patient or tumor markers such as carcinoembryonic antigen (CEA)